文献速递癫痫神经免疫

弥合差距:量身定制发热感染相关性癫痫综合征的治疗方法

Bridging the Gap: Tailoring an Approach to Treatment in Febrile Infection-Related Epilepsy Syndrome.
PubMed 文献 · Neurology · 2023-02-16

本文报告一名18岁男性在非特异性发热性疾病后出现首次癫痫发作,发展为超难治性癫痫持续状态,经多种抗癫痫药物和全身麻醉剂输注治疗。初始血清和脑脊液细胞因子分析显示IL-6等主要在中枢神经系统升高,符合细胞因子释放综合征。托珠单抗(tocilizumab)在第51天给药后出现显著临床和脑电图反应,系列细胞因子谱在7剂托珠单抗后改善。

要点

  • 发热感染相关性癫痫综合征(FIRES)患者可表现为超难治性癫痫持续状态,需多种抗癫痫药物和麻醉剂治疗。
  • 初始血清和脑脊液细胞因子分析显示IL-6、IL-1RA、MCP-1、MIP-1β和IFN-γ主要在中枢神经系统升高。
  • 托珠单抗可能可考虑用于IL-6上调的FIRES患者。

核心结论

  • 本病例说明个体化免疫监测可能有助于FIRES的治疗,其中促炎细胞因子被推测参与癫痫发生。
  • 细胞因子谱分析和与免疫学家的密切合作在FIRES治疗中正发挥新兴作用。
  • 托珠单抗可能可考虑用于IL-6上调的FIRES患者。

研究设计与样本

  • 本文为病例报告,报告一名18岁男性在非特异性发热性疾病后出现首次癫痫发作。

主要发现

  • 患者发展为超难治性癫痫持续状态,需要多种抗癫痫药物和全身麻醉剂输注。
  • 患者接受脉冲式甲泼尼龙和血浆置换治疗,并开始生酮饮食。
  • 增强MRI脑部显示发作后改变,EEG显示多灶性发作性放电和全面性周期性癫痫样放电。
  • 脑脊液分析、自身抗体检测和恶性肿瘤筛查无异常,基因检测显示CNKSR2和OPN1LW基因意义未明变异。
  • 入院第6天和第21天初始血清和脑脊液细胞因子分析显示IL-6、IL-1RA、单核细胞趋化蛋白-1、巨噬细胞炎症蛋白1β和干扰素γ主要在中枢神经系统升高,符合细胞因子释放综合征。

关键数值与推荐

  • 托法替尼(tofacitinib)最初于入院第30天试用,无临床改善,IL-6继续上升。
  • 托珠单抗于第51天给药,出现显著临床和脑电图反应。
  • 阿那白滞素(anakinra)随后于第99天至第103天试用,因停用麻醉剂后临床发作活动重新出现,但因反应不佳而停止。
  • 系列细胞因子谱显示7剂托珠单抗后改善,癫痫控制相应改善。

临床怎么用

  • 作者认为个体化免疫监测可能有助于FIRES病例的治疗。
  • 作者认为细胞因子谱分析和与免疫学家的密切合作在FIRES治疗中正发挥新兴作用。
  • 作者认为托珠单抗可能可考虑用于IL-6上调的FIRES患者。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cytokine profiling before immunotherapy is increasingly prevalent in febrile infection-related epilepsy syndrome (FIRES). In this case, an 18-year-old man presented with first-onset seizure after a nonspecific febrile illness. He developed super-refractory status epilepticus requiring multiple antiseizure medications and general anesthetic infusions. He was treated with pulsed methylprednisolone and plasma exchange and started on ketogenic diet. Contrast-enhanced MRI brain revealed postictal changes. EEG findings showed multifocal ictal runs and generalized periodic epileptiform discharges. CSF analysis, autoantibody testing, and malignancy screening were unremarkable. Genetic testing revealed variants of uncertain significance in the CNKSR2 and OPN1LW genes. Initial serum and CSF cytokine analyses performed on days 6 and 21 revealed that interleukin (IL)-6, IL-1RA, monocyte chemoattractant protein-1, macrophage inflammatory protein 1β, and interferon γ were elevated predominantly in the CNS, a profile consistent with cytokine release syndrome. Tofacitinib was initially trialed on day 30 of admission. There was no clinical improvement, and IL-6 continued to rise. Tocilizumab was given on day 51 with significant clinical and electrographic response. Anakinra was subsequently trialed from days 99 to 103 because clinical ictal activity re-emerged on weaning anesthetics but stopped because of poor response. Serial cytokine profiles showed improvement after 7 doses of tocilizumab. There was corresponding improved seizure control. This case illustrates how personalized immunomonitoring may be helpful in cases of FIRES, where proinflammatory cytokines are postulated to act in epileptogenesis. There is an emerging role for cytokine profiling and close collaboration with immunologists for the treatment of FIRES. The use of tocilizumab may be considered in patients with FIRES with upregulated IL-6.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Goh Y, Tay SH, Yeo LLL, et al. Bridging the Gap: Tailoring an Approach to Treatment in Febrile Infection-Related Epilepsy Syndrome. Neurology. 2023. PMID: 36797068. doi:10.1212/WNL.0000000000207068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。